Comparative pharmacokinetics of HD203, a biosimilar of etanercept, with marketed etanercept (Enbrel®): a double-blind, single-dose, crossover study in healthy volunteers.
作者： SoJeong Yi , Sung Eun Kim , Min-Kyu Park , Seo Hyun Yoon , Joo-Youn Cho
DOI: 10.2165/11631860-000000000-00000
关键词: Biosimilar 、 Pharmacology 、 Crossover study 、 Etanercept 、 Healthy volunteers 、 Double blind 、 Medicine 、 Juvenile rheumatoid arthritis 、 Bioequivalence 、 Pharmacokinetics
摘要: Objective: HD203 is a biosimilar of etanercept, fusion protein the ligand-binding portion human tumor necrosis factor receptor II linked to Fc immunoglobulin G1. Since under clinical development, this study was conducted compare pharmacokinetics with Enbrel ®, first marketed etanercept.
springer.com
sci-hub.se 参考文章(17)
Heinz Lubenau, Peter Bias, Anne-Katrin Maly, Karl Ernst Siegler, Kai Mehltretter, Pharmacokinetic and Pharmacodynamic Profile of New Biosimilar Filgrastim XM02 Equivalent to Marketed Filgrastim Neupogen® BioDrugs. ,vol. 23, pp. 43- 51 ,(2009) , 10.2165/00063030-200923010-00005
H O Adami, Å Rimsten, B Stenkvist, J Vegelius, Influence of height, weight and obesity on risk of breast cancer in an unselected Swedish population. British Journal of Cancer. ,vol. 36, pp. 787- 792 ,(1977) , 10.1038/BJC.1977.263
Kwang Seok Seo, Jin Wook Yoon, Kyu Heum Na, Eun Jeong Bae, Jung Gyu Woo, Sung Hee Lee, Soo Hyoung Kang, Jai Myung Yang, Evaluation of process efficiency and bioequivalence of biosimilar recombinant human chorionic gonadotropin (rhCG). BioDrugs. ,vol. 25, pp. 115- 127 ,(2011) , 10.2165/11589430-000000000-00000
Yi Fang, Lu-jin Li, Rui Wang, Feng Huang, Hai-feng Song, Zhong-ming Tang, Yu-zhen Li, Hua-shi Guan, Qing-shan Zheng, Population pharmacokinetics of rhTNFR-Fc in healthy Chinese volunteers and in Chinese patients with Ankylosing spondylitis Acta Pharmacologica Sinica. ,vol. 31, pp. 1500- 1507 ,(2010) , 10.1038/APS.2010.113
Honghui Zhou, Virginia Parks, Alain Patat, Franck Le Coz, Donna Simcoe, Joan Korth-Bradley, Absence of a Clinically Relevant Interaction Between Etanercept and Digoxin The Journal of Clinical Pharmacology. ,vol. 44, pp. 1244- 1251 ,(2004) , 10.1177/0091270004268050
Richard Stanhope, Fritz Sörgel, Patricia Gravel, Yannic B. Pannatier Schuetz, Markus Zabransky, Michael Muenzberg, Bioequivalence Studies of Omnitrope, the First Biosimilar/rhGH Follow‐on Protein: Two Comparative Phase 1 Randomized Studies and Population Pharmacokinetic Analysis The Journal of Clinical Pharmacology. ,vol. 50, pp. 1339- 1348 ,(2010) , 10.1177/0091270009359005
John T. Sullivan, Liyun Ni, Claudia Sheelo, Margaret Salfi, Paul M. Peloso, Bioequivalence of Liquid and Reconstituted Lyophilized Etanercept Subcutaneous Injections The Journal of Clinical Pharmacology. ,vol. 46, pp. 654- 661 ,(2006) , 10.1177/0091270006287705
Honghui Zhou, Alain Patat, Virginia Parks, Mary Buckwalter, Deborah Metzger, Joan Korth-Bradley, Absence of a Pharmacokinetic Interaction between Etanercept and Warfarin The Journal of Clinical Pharmacology. ,vol. 44, pp. 543- 550 ,(2004) , 10.1177/0091270004264164
Paul Anderson, James Louie, Anna Lau, Michael Broder, None, Mechanisms of differential immunogenicity of tumor necrosis factor inhibitors. Current Rheumatology Reports. ,vol. 7, pp. 3- 9 ,(2005) , 10.1007/S11926-005-0002-2
A. MARZO, Open questions on bioequivalence: some problems and some solutions. Pharmacological Research. ,vol. 40, pp. 357- 368 ,(1999) , 10.1006/PHRS.1999.0528